Increased lipid peroxidation in patients with pulmonary hypertension.

Isoprostanes are chemically stable lipid peroxidation products of arachidonic acid, the quantification of which provides a novel approach to the assessment of oxidative stress in vivo. The main objective of this study was to quantify the urinary levels of isoprostaglandin F(2alpha) type III (iPF(2alpha)-III), an F(2)-isoprostane, in patients with pulmonary hypertension (PHT) in comparison with healthy controls. The secondary objective was to test whether baseline iPF(2alpha)-III levels correlate to the reversibility of pulmonary hypertension in response to inhaled NO challenge. Urinary iPF(2alpha)-III levels were measured by gas chromatography-mass spectrometry in 25 patients with PHT, 14 of whom were investigated for response to inhaled NO challenge. Urinary iPF(2alpha)-III levels in PHT patients (225 +/- 27 pmol/mmol creatinine) were 2.3 times as high as in controls (97 +/- 7 pmol/mmol creatinine, p < 0.001). The mean pulmonary arterial pressure variation and the pulmonary vascular resistance variation in response to inhaled NO were correlated to basal iPF(2alpha)-III levels. This study shows that oxidative stress is increased in patients with pulmonary hypertension. Furthermore, iPF(2alpha)-III levels inversely correlate to pulmonary vasoreactivity. These observations are consistent with the hypothesis that free radical generation is involved in PHT pathogenesis.

[1]  J. Cracowski,et al.  Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. , 2001, Arthritis and rheumatism.

[2]  J. Cracowski,et al.  Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[3]  P. Devillier,et al.  Vascular Biology of the Isoprostanes , 2001, Journal of Vascular Research.

[4]  C. Giagulli,et al.  8-Iso-PGF2&agr; Induces &bgr;2-Integrin–Mediated Rapid Adhesion of Human Polymorphonuclear Neutrophils: A Link Between Oxidative Stress and Ischemia/Reperfusion Injury , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[5]  G. Davı̀,et al.  In vivo lipid peroxidation and platelet activation in cystic fibrosis. , 2000, American journal of respiratory and critical care medicine.

[6]  L. Wood,et al.  Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma , 2000, Lipids.

[7]  N. Lazzeri,et al.  Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. , 2000, American journal of respiratory and critical care medicine.

[8]  E. Anggard,et al.  Evaluation of the postprandial effects of a fast-food meal on human plasma F(2)-isoprostane levels. , 2000, Free radical biology & medicine.

[9]  Massimo Corradi,et al.  Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis , 2000, Thorax.

[10]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[11]  D. Rodríguez‐Puyol,et al.  Reactive oxygen species induce proliferation of bovine aortic endothelial cells. , 2000, Journal of cardiovascular pharmacology.

[12]  J. Morrow,et al.  Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. , 1999, American journal of respiratory and critical care medicine.

[13]  S. Métairon,et al.  Urinary isoprostane excretion is not confounded by the lipid content of the diet , 1999, FEBS letters.

[14]  P. Montuschi,et al.  Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. , 1999, American journal of respiratory and critical care medicine.

[15]  T. Evans,et al.  Isoprostanes and PGE2 production in human isolated pulmonary artery smooth muscle cells: concomitant and differential release , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  L. Wood,et al.  Elevated plasma levels of F2α isoprostane in cystic fibrosis , 1999, Lipids.

[17]  G. Davı̀,et al.  In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus , 1999 .

[18]  R. Fanelli,et al.  Identification and Measurement of Endogenous β-Oxidation Metabolites of 8-epi-Prostaglandin F2α* , 1999, The Journal of Biological Chemistry.

[19]  M. Reilly,et al.  Increased formation of distinct F2 isoprostanes in hypercholesterolemia. , 1998, Circulation.

[20]  B. Christman,et al.  Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. , 1998, Chest.

[21]  G. FitzGerald,et al.  Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. , 1998, American journal of respiratory and critical care medicine.

[22]  Y. Lai,et al.  Antioxidants attenuate chronic hypoxic pulmonary hypertension. , 1998, Journal of cardiovascular pharmacology.

[23]  P. Montuschi,et al.  8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. , 1998, American journal of respiratory and critical care medicine.

[24]  L. Roberts,et al.  Measurement of lipid peroxidation. , 1998, Free radical research.

[25]  M. Hallman,et al.  Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure. , 1998, The Journal of pediatrics.

[26]  D. Thibeault,et al.  Eight-epi-PGF2alpha: a possible marker of lipid peroxidation in term infants with severe pulmonary disease. , 1998, The Journal of pediatrics.

[27]  E. Mohler,et al.  Role of 8-epi PGF2alpha, 8-isoprostane, in H2O2-induced derangements of pulmonary artery endothelial cell barrier function. , 1998, Prostaglandins, leukotrienes, and essential fatty acids.

[28]  G. FitzGerald,et al.  Nomenclature of isoprostanes: a proposal. , 1997, Prostaglandins.

[29]  J. Valentin,et al.  Analysis of the pulmonary hypertensive effects of the isoprostane derivative, 8‐iso‐PGF2α, in the rat , 1997, British journal of pharmacology.

[30]  C. Weare,et al.  Characterization of signal transduction events stimulated by 8-epi-prostaglandin(PG)F2 alpha in rat aortic rings. , 1997, Prostaglandins.

[31]  D. Praticò,et al.  8-Epi PGF2α Generation During Coronary Reperfusion , 1997 .

[32]  T. Evans,et al.  Release of isoprostanes by human pulmonary artery in organ culture: a cyclo-oxygenase and nitric oxide dependent pathway. , 1997, Biochemical and biophysical research communications.

[33]  T. Evans,et al.  Evidence for a dilator function of 8‐iso prostaglandin F2α in rat pulmonary artery , 1997 .

[34]  J. Morrow,et al.  A nomenclature system for the isoprostanes. , 1997, Prostaglandins.

[35]  M. Baraldi,et al.  Measurement of urinary 8-Epi-prostaglandin F2alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers. , 1996, Free radical biology & medicine.

[36]  G. FitzGerald,et al.  Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[37]  J. Morrow,et al.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. , 1995, The New England journal of medicine.

[38]  A. Denjean,et al.  Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.

[39]  P. Hickey,et al.  Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension , 1994, Critical care medicine.

[40]  J. Morrow,et al.  Airway and vascular effects of 8-epi-prostaglandin F2 alpha in isolated perfused rat lung. , 1993, Journal of applied physiology.

[41]  A. L. Goldin,et al.  Protein kinase A phosphorylation enhances sodium channel currents in Xenopus oocytes. , 1992, The American journal of physiology.

[42]  T. Higenbottam,et al.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension , 1991, The Lancet.

[43]  Z. Katušić,et al.  Contractions to Oxygen‐Derived Free Radicals Are Augmented in Aorta of the Spontaneously Hypertensive Rat , 1989, Hypertension.

[44]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[45]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.